Company Analysis

Xenon Pharmaceuticals Inc. (XENE)

Nasdaq: XENE · Pharmaceutical Preparations · filing with the SEC since 2013
Grade4.6
◀ Past 4.3● Present 5.1▶ Future 4.4
2 est.

Who runs Xenon Pharmaceuticals Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Mortimer Ian
PRESIDENT & CEO. First filing Nov 2014, latest Oct 1, 2026, 11 filings in all.
Officers reporting now
5
of 12 people with a filing in the last fifteen months
Directors reporting now
7
27 people on the record since 2014
Officerssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Kelly Thomas PatrickChief Financial OfficerOct 2025Oct 16, 2026none
Mortimer IanPRESIDENT & CEONov 2014Oct 1, 202617 · $20.3M
Kenney Christopher JohnChief Medical OfficerAug 2021Aug 31, 20264 · $700,000
Difabio AndreaChief Legal OfficerNov 2022Mar 13, 20262 · $200,000
Cline Darren SChief Commercial OfficerJun 2025Jan 9, 2026none
Directorssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameRoleFirst filingLatest filingSales, 12 months
Svoronos DawndirectorSep 2016Sep 3, 2026none
Gannon StevendirectorMay 2015Aug 13, 20261 · $600,000
Cannon GilliandirectorAug 2023Jun 8, 20261 · $100,000
Patou GarydirectorNov 2014Jun 8, 20261 · $100,000
Garofalo Elizabeth A.directorJun 2021Jun 3, 2026none
Gover Justin D.directorAug 2023Jun 3, 2026none
Machado PatrickdirectorNov 2020Jun 3, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton XENE · research, not advice